Success in SF: Precision Oncology Summit receives Abstracts from a Combined Total of 125 Authors

125 Authors Respond to Call for Abstracts

The 6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy in San Francisco received abstracts from a combined total of 125 authors.

Co-chaired by Mark Daniel Pegram, MD and James M Ford, MD, the summit will include another installment of the Impact Pitch Research Challenge. Early-career researchers and oncologists pitch their abstracts for the chance to earn the Binaytara Precision Oncology Research Award of up to $25,000. This year’s catalysts are Mark Daniel Pegram, MD; James M. Ford, MD; James Brugarolas, MD, PhD; and Trever Bivona, MD, PhD. These catalysts specialize in various cancers and cancer subtypes to offer different perspectives to those pitching. Each researcher also comes from a different university, with Bivona and Pegrem representing Northern California universities UCSF and Stanford respectively. The moderator, Varun Monga, MD, MBBS, will steer conversation topics and ensure every researcher has the chance to take the floor.

This Precision Oncology Summit received 26 abstracts from a combined total of 125 authors from 40 institutions. There are six countries represented this year: The United States, India, Italy, Grenada, Tunisia, and China. Researchers who submitted abstracts are welcome to submit complete manuscripts for publication with the International Journal of Cancer Care and Delivery (IJCCD).

Best of the Best: The Research Accepted for Oral Abstract Presentation

The Precision Oncology Summit call for abstracts received a global response. Four submissions were accepted for oral abstract presentation at the conference, each grounded in advancing precision medicine in cancer care. Below are details of the abstracts accepted for oral presentation:

Polymerase θ as a Target for Synthetic Lethality in APOBEC3A-high Cancer

Abhishek Bose (Weill Cornell Medicine)

Targeting SEMA7A in pre-clinical models of treatment resistant Breast Cancer

Traci Lyons (University of Colorado Anschutz Medical Cancer Center)

First-in-Human Phase I Trial of Drug-Regulatable B7-H3 CAR T Cells for Advanced Solid Tumors

Alexander Salter (Stanford University), Allison Betof (Stanford University), Crystal Mackall (Stanford University)

Genomic landscape of TP53 Y220C–mutated clinically advanced prostate carcinoma (CAPC)

Varun Nandakumar (Huntsman Cancer Institute at the University of Utah), Neeraj Agarwal (Huntsman Cancer Institute at the University of Utah), Philippe E. Spiess (Moffitt Cancer Center), Roger Li (Moffitt Cancer Center), Petros Grivas (Fred Hutch Cancer Center), Sumanta Kumar Pal (City of Hope Comprehensive Cancer Center), Ashish M. Kamat (MD Anderson Cancer Center), Shilpa Gupta (Cleveland Clinic), Andrea Necchi (San Raffaele Hospital and Scientific Institute), Liang Cheng (Department of Hematology and Oncology, Brown University), Douglas I. Lin (Foundation Medicine), Ole Gjoerup (Foundation Medicine), Jerry W. Mitchell (Foundation Medicine), Ryon P. Graf (Foundation Medicine), Jeffrey S. Ross (Foundation Medicine), Joseph M. Jacob (SUNY Upstate Medical University), Gennady Bratslavsky (SUNY Upstate Medical University), Alina Basnet (Renzi Cancer Center)

Origins of the Impact Pitch

The most recent Impact Pitch competition took place at the Summit on Cancer Health Disparities (SCHD26). At this summit, the Binaytara Implementation Science Research Award was given to researchers Dr. Benjamin Li of Fred Hutchinson Cancer Center and the University of Washington, and Dr. Akshee Batra of the Sylvester Comprehensive Cancer Center at the University of Miami. Both awardees pitched research aimed to close gaps in care and provide patients with vital educational information. Following Batra and Li, Sylvester Comprehensive Cancer Center’s Dr. Chinmay Jani took home the Lung Cancer Research Award at Binaytara’s recent Brooklyn Lung Cancer Conference.

The Impact Pitch will continue to take place later this year at the 2026 National Summit on Hematologic Cancers in Nashville and 2026 Seattle Lung Cancer Conference this October. At the Nashville Summit, the Shaji Kumar Hematology Research Award is split into two categories: early-career faculty awards and fellow awards. This provides more opportunity for funding and developing innovative research on hematologic malignancies.

This year’s catalysts for the upcoming Precision Oncology Summit are looking for how research can positively impact the longevity of treatment, patient outcomes, and the field of preventive medicine, each drawing from significant clinical success in the field. Join this year’s presenters and catalysts in San Francisco on September 11 and 12 to see the next generation of precision oncology research unfold.